[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647451":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":7,"responsibleParty":25,"collaborators":7,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":7,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":7,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":35,"phases":7,"briefSummary":36,"conditions":37,"keywords":39,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":45,"locationsCount":7},{"fullName":5,"class":6},"Synermore Biologics (Suzhou) Co., Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Zamerovimab and Mazorelvimab Injection","SYN023 may be administered with rabies treatments according to the local standard of care; local standard of care may include the Milwaukee Protocol if the treating clinician and patient so choose.",[14],"SYN023",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Eric Tsao","CONTACT","+86 18550278707","etsao@synermore.com",{"name":22,"role":18,"phone":23,"phoneExt":7,"email":24},"Xiangjun Li","+86 18898880617","xjli@synermore.cn",{"type":26,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100647451","an-expanded-access-program-for-syn023-in-rabies-treatment-100647451",false,"NCT07706907","An Expanded Access Program for SYN023 in Rabies Treatment","Sponsor-Initiated Expanded Access Program (SYN023-EAP-001) for SYN023 (Zamerovimab + Mazorelvimab): Compassionate Use of SYN023 in Patients With Confirmed or Suspected Life-Threatening Rabies Infection","Inclusion Criteria:\n\n* Must be ineligible for or lack access to other investigational or approved therapies\n* Must have no available alternative curative treatment options\n\nExclusion Criteria:\n\nNo standardized universal exclusion criteria are predefined for this Expanded Access Program.\n\n\\- Clinical contraindications identified on an individual basis by the treating critical care clinician","ALL","EXPANDED_ACCESS","This sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected life-threatening rabies lacking adequate alternative therapies.",[38],"Rabies",[38,14],"AVAILABLE","2026-07-16",{"date":43,"type":44},"2026-07-17","ACTUAL",{"name":5,"class":6}]